Company intelligence / Profile preview

ZOXIZO

Ownership: Private
Development stage: Other

Overview

Zoxizo is an early-stage biotechnology company focused on the development of novel small molecule therapeutics targeting inflammatory pathways. The company's primary research centers on the inhibition of Caspase-1, a key enzyme in the inflammasome complex responsible for the maturation of pro-inflammatory cytokines. By modulating these pathways, Zoxizo aims to provide new treatment options for patients suffering from chronic inflammatory and autoimmune conditions. The company is currently advancing its lead candidates through pre-clinical validation and optimization.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on ZOXIZO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZOXIZO.

Explore the full profile